Fig. 1

Overexpression of NAV2 in CRC and was associated with more aggressive tumor stage: a Immunohistochemical staining of NAV2 with increased score ranged from stageIto IV in CRC patients from cohort 1. Magnification: ×400; scale bar, 50 μm. NAV2 mRNA level was detected by qRT-PCR in CRC patients from cohort 2 (B-D): b, Tumor tissues (T) were higher than paired normal tissues (NT) (*P < 0.0001); c, Metastatic sites (MS) were higher than primary tumors (PT) (**P = 0.0142); d, Stage III/IV with higher expression level than satgeI/II (***P < 0.0001). Expression levels were normalized to those of β-actin (2^-ΔΔCT). Western blotting was used to analysis NAV2 protein expression level in CRC patients from cohort 2 (e, f, g), the dates were shown in the Additional file 3: Figure S1. h NAV2 protein expression level in various metastatic potency CRC cells and other cell lines were tested by Western blotting, NAV2 was high expression in high metastatic potency cells, experiments have been repeated three times